Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Identifying Prediabetic Patients Using Administrative Claims Linked With Lab Data To Assess Progression To Type 2 Diabetes

ISPOR 2024

International Society for Pharmacogenomics and Outcomes Research

Atlanta, GA, May 5-8, 2024

Poster presentation: Identifying Prediabetic Patients Using Administrative Claims Linked With Lab Data To Assess Progression To Type 2 Diabetes

Authors: Ip Q, Wu X, Chin A, Pham N, Rehan W

Specialty: Cardiology, Endocrinology

Related content

On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Publication
Predictors of lack of glycemic control in persons with type 2 diabetes
Publication
Impact of a Digital Diabetes Prevention Program on Risk factors for Chronic Disease in a Workforce Cohort
Publication
Prognostic value of insulin resistance and hyperglycemia biomarkers for long-term risks of cardiometabolic outcomes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.